Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19206729 | 0.93 | BACE1 (0.36) | CDC7CHEK2XDHGABRA1GABRB2 | |
| SCHEMBL12293879 | 0.93 | ABCB1 (0.42) | ABCB1CDC7PARP1XDHADORA3 | |
| SCHEMBL64690 | 0.93 | ABCB1 (0.42) | ABCB1CDC7PARP1XDHADORA3 | |
| SCHEMBL954434 | 0.92 | ABCB1 (0.41) | ABCB1CDC7PARP1XDHADORA3 | |
| SCHEMBL2680751 | 0.91 | ABCB1 (0.40) | ABCB1CDC7PARP1XDHADORA3 | |
| SCHEMBL10196910 | 0.90 | PARP1 (0.38) | ABCB1CDC7PARP1XDHADORA3 | |
| SCHEMBL17696238 | 0.89 | PTGS2 (0.33) | CDC7CHEK2XDHGABRA1GABRB2 | |
| SCHEMBL21531540 | 0.89 | KDM4E (0.37) | ABCB1ALDH1A1 | |
| SCHEMBL20841761 | 0.88 | ABCB1 (0.39) | ABCB1CDC7GABRA1GABRB2ADORA3 | |
| SCHEMBL20841749 | 0.88 | ABCB1 (0.39) | ABCB1CDC7PARP1XDHPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY | 2024-07-18 | — | — | US | disclosed |
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY | 2024-07-18 | — | — | US | disclosed |
| US-20210332044-A1 | SYNTHESIS OF COELENTERAZINE SYNTHESIS INTERMEDIATE | INTERNATIONAL PAPER COMPANY (US) | 2021-10-28 | — | — | US | disclosed |
| US-11078200-B2 | Synthesis of coelenterazine | INTERNATIONAL PAPER COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| US-11008326-B2 | Synthesis of coelenterazine | INTERNATIONAL PAPER COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210070762-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY (US) | 2021-03-11 | — | — | US | disclosed |
| US-10906911-B2 | — | — | 2021-02-02 | — | — | US | disclosed |
| US-20200239471-A1 | SYNTHESIS OF COELENTERAZINE | ALLY BANK, AS COLLATERAL AGENT | 2020-07-30 | — | — | US | disclosed |
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9645128-B2 | Substituted imidazo[1,2-A]pyrazines for measuring a transcription activity | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-8765921-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024058-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546568-B2 | Coelenterazine analogs and manufacturing method thereof | JNC CORPORATION (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010090319-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | チッソ株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100105090-A1 | SECRETED LUCIFERASE MLUC7 AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105090-A1 | SECRETED LUCIFERASE MLUC7 AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105090-A1 | SECRETED LUCIFERASE MLUC7 AND USE THEREOF | LUC7L2, MRPL37, TCF7 | ABCB1 3223/4885CDC7 526/4885ALOX5 4534/4885 |
| US-11008326-B2 | Synthesis of coelenterazine | ACHE, UROD, DDT | ABCB1 1652/4885CDC7 805/4885ALOX5 804/4885 |
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | ACHE, UROD, DDT | ABCB1 1652/4885CDC7 805/4885ALOX5 804/4885 |
| US-20210070762-A1 | SYNTHESIS OF COELENTERAZINE | ACHE, UROD, DDT | ABCB1 1652/4885CDC7 805/4885ALOX5 804/4885 |
| US-10906911-B2 | — | ACHE, UROD, SI | ABCB1 1174/4885CDC7 1170/4885ALOX5 454/4885 |
| US-20120035070-A1 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | GLB1, CEL, SI | ABCB1 1068/4885CDC7 2192/4885ALOX5 1352/4885 |
| US-11078200-B2 | Synthesis of coelenterazine | ACHE, UROD, DDT | ABCB1 1652/4885CDC7 805/4885ALOX5 804/4885 |
| US-20200239471-A1 | SYNTHESIS OF COELENTERAZINE | ACHE, UROD, DDT | ABCB1 1652/4885CDC7 805/4885ALOX5 804/4885 |
| US-20210332044-A1 | SYNTHESIS OF COELENTERAZINE SYNTHESIS INTERMEDIATE | DCXR, SI, UROD | ABCB1 1854/4885CDC7 853/4885ALOX5 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.